I use my wide breadth of knowledge to keep my audience in the pharmaceutical industry informed of the latest developments of FDA policy that have a clear impact on their business and many people’s personal health. This includes a focus on putting single events into a larger context and providing detailed analysis that my readers can act on. For example, among the many in-depth pieces I did In 2014, I exposed a regulatory gap in disease-awareness advertising regulation that may benefit drug companies but hurt patients. I also highlighted potential flaws in FDA’s drug shortage prevention strategies, showed how reimbursement issues are creeping into FDA’s arena despite the agency’s lack of authority over drug prices, and uncovered conflicting FDA actions related to cardiovascular outcomes trials.
